Genetics Research

Genetics Research / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 9925272 | https://doi.org/10.1155/2021/9925272

Fen-Han Zhang, Rui-Xing Yin, Li-Mei Yao, Wei-Xiong Lin, Jin-Zhen Wu, De-Zhai Yang, "Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations", Genetics Research, vol. 2021, Article ID 9925272, 12 pages, 2021. https://doi.org/10.1155/2021/9925272

Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations

Academic Editor: Chaeyoung Lee
Received24 Mar 2021
Accepted22 Jun 2021
Published03 Jul 2021

Abstract

The association between the phospholipid transfer protein (PLTP) gene rs4810479 single-nucleotide polymorphism (SNP) and serum lipid levels is largely unknown. This investigation aimed to evaluate the relationship between the PLTP rs4810479 SNP, several environmental risk factors, and serum lipid parameters in the Chinese Maonan and Han nationalities. Polymerase chain reaction-restriction fragment length polymorphism, gel electrophoresis, and direct sequencing were employed to determine the PLTP rs4810479 genotypes in 633 Maonan and 646 Han participants. The frequencies of CC, CT, and TT genotypes and the C allele were different between Maonan and Han groups (29.07%, 53.08%, 17.85%, and 55.61% vs. 35.60%, 49.70%, 14.70%, and 60.45%, respectively, ). The C allele carriers in the Maonan group had higher high-density lipoprotein cholesterol levels than the C allele noncarriers, but this finding was only found in Maonan males but not in females. The C allele carriers in Han males had lower total cholesterol and low-density lipoprotein cholesterol levels than the C allele noncarriers. Serum lipid profiles were also affected by several traditional cardiovascular risk factors in both populations. There might be an ethnic- and/or sex-specific association between the PLTP rs4810479 SNP and serum lipid traits.

1. Introduction

Cardiovascular disease (CVD) is one of the leading causes of disability and early death worldwide, accounting for about one-third of the global mortality rate [1]. The cost of CVD constitutes a major economic burden to the society [2]. Many studies have proven that serum or plasma triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) concentrations are independent risk factors for CVD [35].

It is well known that various genetic and environmental factors can lead to abnormalities of plasma lipids and lipoproteins [68]. Plasma lipid and lipoprotein concentrations are themselves highly heritable—estimates range from 40% to 60%. A number of genome-wide association studies (GWASes) have identified more than 95 genetic loci associated with plasma lipid phenotypes. One of the newly discovered loci is the phospholipid transfer protein (PLTP) gene [912].

PLTP (also called lipid transfer protein 2) is a member of lipid transfer/lipopolysaccharide- (LPS-) binding protein family. This family includes PLTP, LPS-binding protein (LBP), bactericidal/permeability-increasing protein (BPI), and cholesterol ester transfer protein (CETP) [1315]. There are two molecular weights of PLTP, 55 kDa and 81 kDa. This may be due to different glycosylation [15]. PLTP is a monomeric and nonspecific lipid transfer protein, which can efficiently transfer free cholesterol, diacylglycerol, α-tocopherol, cerebroside, LPS, phospholipids, and sphingosine-1-phosphate [1315]. There are two forms of lipoprotein-associated plasma PLTP (high active one and low active one) which are associated with apolipoprotein (Apo) A1- and ApoE-containing lipoproteins, respectively [16]. However, the cause for the existence of active and inactive PLTP in plasma is unclear. It is quite possible that PLTP might have other activities except its lipid transfer function [15]. PLTP is produced in various types of cells and secreted into plasma. It is highly expressed in human tissues such as the ovary, thymus, placenta, lung [17], liver, and small intestine and in macrophages [18, 19] and atherosclerotic lesions [19, 20]. The gene encoding PLTP (PLTP) is located on human chromosome 20. Its cDNA has a length of 1750 base pairs, including an open reading frame of 1518 nucleotides and a 3′-untranslated region (UTR) of 184 nucleotides. The mature PLTP contains 476 amino acids and 6 N-glycosylation sites that allow it to change its molecular weight (55 or 81 kDa) after different degrees of glycosylation modification [17]. Several previous studies have found that PLTP is an emerging cardiac metabolic factor which exerts a vital part in the development of blood lipid metabolism and atherosclerosis [21, 22]. PLTP is a main factor modulating the size and composition of high-density lipoprotein particles in the circulation and plays an important role in controlling plasma HDL-C levels [23]. PLTP deficiency in mice can lower total cholesterol (TC), HDL-C, and ApoA1 but increase TG levels significantly, impact the biological quality of high-density lipoprotein [24], and attenuate high-fat diet-induced insulin resistance and obesity [25]. Plasma PLTP activity (PLTPa) was significantly inversely correlated with carotid artery disease (CAAD), with a 9% decrease in odds of CAAD per 1 unit increase in PLTPa. Plasma TG levels, diabetes, statin use, and PLTP rs4810479 SNP were also associated with PLTPa significantly [26]. In human studies, both PLTP mass and PLTPa were associated with plasma lipid traits, glucose regulation, and atherosclerosis. Common variation at the PLTP structural locus region could explain about 30% of variation in PLTPa [27]. PLTP variants were associated with the PLTP mRNA level [28] and CVD risk [27, 29].

Being an isolated and conservative minority in China, the population of Maonan nationality was 107,166 (ranked 37) according to the statistics of China’s sixth national census in 2010. They have own unique culture and life customs, such as intraethnic marriages, clothing, special lifestyle, and dietary structure. These characteristics are distinct from those in the largest ethnic group, Han Chinese. Therefore, we hypothesize that the genotype distribution and genetic traits of some lipid metabolism-related genes in the Maonan ethnic group may be different from those in the Han ethnic group. In the Chinese populations, there is no previous study to explore the association between the PLTP rs4810479 SNP and serum lipid levels. Thus, the aim of this study was to appraise the association between the PLTP rs4810479 SNP, several environmental risk factors, and serum lipid traits in the Maonan and Han nationalities.

2. Materials and Methods

2.1. Subjects

The study populations were stochastically chosen from our earlier stratified random specimens. The detailed inclusion and exclusion criteria have been described in a previous report [30]. In brief, all selected people were basically healthy and had no evidence of any chronic illness such as cardiac, hepatic, renal, or thyroid diseases. The participants who had a history of heart attack or myocardial infarction, stroke, congestive heart failure, and diabetes were excluded. They did not use medications known to affect serum lipid levels such as lipid-lowering drugs (statins or fibrates), β-blockers, diuretics, or hormones. The present study included 633 unrelated Maonan participants (251 males, 39.65%, and 382 females, 60.35%) and 646 unrelated Han subjects (268 males, 41.49%, and 378 females, 58.51%) [30]. The participants aged from 22 to 92 years (mean: 55.92 ± 14.30 years in Maonan and 54.50 ± 14.50 years in Han groups). The age structure and sex ratio between the two populations were matched. Basic information and health status of all participants refer to our previous study [31]. This research project was approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University (no. Lunshen-2014-KY-Guoji-001, March 7, 2014). All participants provided written informed consent before the study.

2.2. Epidemiological Survey

The survey was conducted using an internationally standardized method [32]. A standardized questionnaire was used to gather the information related to demographic statistics, socioeconomic status, and life style factors. Drinking and smoking were grouped according to daily consumption (0, ≤25, and >25 and 0, ≤20, and >20, respectively). Several parameters such as weight, body mass index (BMI), height, waist circumference, and blood pressure were also obtained.

2.3. Biochemical Measurements

After 12 hours of fasting, a cubital vein blood sample of 5 ml was obtained from all participants. Biochemical measurements including TC, TG, HDL-C, LDL-C, ApoA1, ApoB, and blood glucose were performed as previously described [33, 34].

2.4. DNA Amplification and Genotyping

Genomic DNA of the samples was extracted by the phenol-chloroform method [34]. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was utilized to determine the genotypes of the PLTP rs4810479 SNP. The forward and reverse primer pairs for PCR amplification were 5′-ATCCTCCGATCTTGGCTTCC-3′ and 5′-CCAGGTAGAGGGAACAGCAA-3′, respectively. The specific reaction condition was 5 min pretreatment at 95°C, denaturation at 95°C for 30 s, annealing at 59°C for 30 s, followed by extension for 40 s at 72°C for 33 cycles, and finally a 7 min extension at 72°C. The restriction enzyme was KpnI. After electrophoresis on 2.0% agarose gel containing 0.5 μg/ml of ethidium bromide, the results were obtained under ultraviolet light. The PCR products of six samples were also confirmed by direct sequencing using ABI Prism 3100 (Applied Biosystems) in Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., China.

2.5. Diagnostic Criteria

The normal reference values of serum lipid parameters including TG, TC, LDL-C, HDL-C, ApoA1, ApoB concentrations, and ApoA1/ApoB ratio as well as the diagnostic criteria of hyperlipidemia, hypertension, and type 2 diabetes, and normal weight, overweight, and obesity have been described in detail in our several previous research studies [30, 31, 3335].

2.6. Statistical Analysis

The number of study samples in this research was estimated using Quanto software. All of the statistical analyses were accomplished using SPSS software (version 23.0). Normally distributed quantitative variables were expressed as mean ± standard deviation (nonnormally distributed serum TG levels were expressed as median and quartiles). Direct counting and standard goodness-of-fit test were used to determine the allele frequency and verify the Hardy–Weinberg equilibrium (HWE), respectively. The genotype distribution was tested by chi-square test, and the general features between the two ethnic groups were analyzed by unpaired t-test. The association between genotype and serum lipid parameters was assessed by the covariance analysis (ANCOVA), in which age, gender, blood pressure, BMI, cigarette smoking, and alcohol consumption were used as covariates. Stepwise modeling of multiple linear regression analyses was used to determine the relevant risk factors for serum lipid parameters in the Maonan, Han, male, and female (CC/CT genotypes = 1 and TT genotype = 2), respectively. Bilateral value <0.05 was considered statistically significant.

3. Results

3.1. General Features and Serum Lipid Profiles

The features and serum lipid levels are presented in Table 1. The values of gender ratio, age structure, BMI, weight, and height; the percentages of cigarette smoking and alcohol intake; the levels of blood glucose, TC, LDL-C, ApoA1, and ApoB; and the ratio of ApoA1/ApoB were not different between the Maonan and Han populations ( for all). However, the levels of waist circumference, pulse pressure, diastolic and systolic blood pressures, and serum TG were higher, whereas the levels of HDL-C were lower in Maonan than in Han ethnic groups .


ParameterMaonanHant (χ2)

Number633646
Male/female251/382268/3780.4460.531
Age (years)55.92 ± 14.3054.50 ± 14.501.7610.079
Height (cm)154.09 ± 8.22154.88 ± 7.82−1.7560.079
Weight (kg)53.58 ± 10.6053.32 ± 8.880.4590.646
Body mass index (kg/m2)22.46 ± 3.6222.20 ± 3.211.3720.170
Waist circumference (cm)76.73 ± 9.0475.09 ± 8.053.4150.001

Smoking status (n (%))
 Nonsmoker500 (79.0)484 (74.9)
 ≤20 cigarettes/day116 (18.3)139 (21.5)3.1030.212
 >20 cigarettes/day17 (2.7)23 (3.6)

Alcohol consumption (n (%))
 Nondrinker499 (78.8)523 (81.0)
 ≤25 g/day71 (11.2)59 (9.1)1.5470.461
 >25 g/day63 (10.0)64 (9.9)

Systolic blood pressure (mmHg)134.49 ± 23.29130.02 ± 19.733.697<0.001
Diastolic blood pressure (mmHg)83.29 ± 11.9981.55 ± 11.012.6980.007
Pulse pressure (mmHg)51.20 ± 16.8448.47 ± 15.772.9890.003
Glucose (mmol/L)6.08 ± 1.256.22 ± 1.33−1.9340.053
Total cholesterol (mmol/L)4.99 ± 0.974.90 ± 0.931.6400.101
Triglyceride (mmol/L)1.28(0.88)1.10(0.65)4.750<0.001
HDL-C (mmol/L)1.62 ± 0.391.83 ± 0.42−9.207<0.001
LDL-C (mmol/L)2.89 ± 0.812.84 ± 0.700.9910.322
ApoA1 (g/L)1.39 ± 0.231.38 ± 0.231.1650.244
ApoB (g/L)0.88 ± 0.190.87 ± 0.201.0320.302
ApoA1/ApoB1.66 ± 0.501.66 ± 0.450.0130.990

HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Apo: apolipoprotein. The value of triglyceride was presented as median (interquartile range); the difference between the two ethnic groups was determined by the Wilcoxon–Mann–Whitney test.
3.2. Genotyping and Genotypes

After electrophoresis of the PCR product, the products of 609 bp nucleotide sequences were observed in all samples (Figure 1). The bands of the three genotypes are presented in Figure 2: CT genotype (286, 323, and 609 bp), CC genotype (286 and 323 bp), and TT genotype (609 bp). The genotypes were distinguished by the presence of the enzyme restriction site (C allele) or absence (T allele). The results of direct sequencing of the samples are shown in Figure 3.

3.3. Genotype and Allele Frequencies

As shown in Table 2, there were significant differences in the frequencies of CC, CT, and TT genotypes and C allele between the Maonan and Han populations (29.07%, 53.08%, 17.85%, and 55.61% vs. 35.60%, 49.70%, 14.70%, and 60.45%, respectively, ). However, the genotype and allele frequencies of the rs4810479 SNP in both ethnic groups were not significantly different between men and women ( for all).


GroupnGenotypeAllele
CCCTTTCT

Maonan633184 (29.07)336 (53.08)113 (17.85)704 (55.61)562 (44.39)0.059
Han646230 (35.60)321 (49.70)95 (14.70)781 (60.45)511 (39.55)0.319
χ26.8806.153
0.0320.014

Maonan
Male25178 (31.08)128 (51.00)45 (17.93)284 (56.57)218 (43.43)0.549
Female382106 (27.79)208 (54.29)68 (17.92)420 (54.97)344 (45.03)0.051
χ20.9190.314
0.6320.603

Han
Male26893 (34.70)140 (52.24)35 (13.06)326 (60.82)210 (39.18)0.116
Female378137 (36.25)181 (47.88)60 (15.87)455 (60.19)301 (39.81)0.987
χ21.5470.053
0.4610.862

HWE: Hardy–Weinberg equilibrium. The genotype distribution between the two groups was analyzed by the chi-square test. The Hardy–Weinberg equilibrium was analyzed by the chi-square test of the goodness of fit.
3.4. Genotypes and Serum Lipid Concentrations

As summarized in Tables 3 and 4, serum HDL-C concentrations in the Maonan group were significantly different among the three genotypes , and serum HDL-C concentrations were higher in the C allele carriers than the C allele noncarriers, but this finding was only restricted to males but not females. Lower TC and LDL-C concentrations in Han males were also observed in the C allele carriers than the C allele noncarriers ( for all).


Group/genotypenTC (mmol/L)TG (mmol/L)HDL-C (mmol/L)LDL-C (mmol/L)ApoA1 (g/L)ApoB (g/L)ApoA1/ApoB

Maonan633

CC1845.00 ± 0.961.22 (0.90)1.61 ± 0.392.91 ± 0.831.39 ± 0.230.89 ± 0.191.64 ± 0.55
CT3365.02 ± 0.971.29 (0.87)1.65 ± 0.402.90 ± 0.791.41 ± 0.240.88 ± 0.191.68 ± 0.49
TT1134.89 ± 0.961.35 (0.86)1.53 ± 0.342.79 ± 0.811.34 ± 0.220.86 ± 0.191.62 ± 0.42
F0.7792.0523.2811.3662.7561.1730.329
0.4590.3580.0380.2560.0640.3100.720
CC/CT5205.01 ± 0.971.26 (0.88)1.64 ± 0.402.91 ± 0.811.40 ± 0.240.89 ± 0.191.67 ± 0.51
F1.509−1.3894.8442.7123.7212.1090.024
0.2200.1650.0280.1000.0540.1470.876

Han646
CC2304.83 ± 0.881.11 (0.47)1.88 ± 0.442.78 ± 0.591.39 ± 0.220.87 ± 0.201.67 ± 0.44
CT3214.94 ± 0.921.12 (0.74)1.79 ± 0.412.85 ± 0.731.36 ± 0.230.87 ± 0.191.65 ± 0.46
TT954.98 ± 1.040.98 (0.87)1.85 ± 0.412.97 ± 0.831.38 ± 0.230.88 ± 0.211.65 ± 0.50
F1.4093.3692.7192.7101.0590.3940.070
P0.2450.1860.0670.0670.3470.6740.933
CC/CT5514.89 ± 0.911.11 (0.62)1.82 ± 0.422.82 ± 0.681.38 ± 0.230.87 ± 0.201.66 ± 0.45
F0.774−1.5781.1323.6150.4570.4930.034
0.3790.1440.2880.0580.4990.4830.853

TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B; ApoA1/ApoB: the ratio of apolipoprotein A1 to apolipoprotein B. The value of TG was presented as median (interquartile range); the difference between the genotypes was determined by the Wilcoxon–Mann–Whitney test.

Ethnic/genotypenTC (mmol/L)TG (mmol/L)HDL-C (mmol/L)LDL-C (mmol/L)ApoA1 (g/L)ApoB (g/L)ApoA1/ApoB

Maonan/male

 CC/CT2064.90 ± 0.891.33 (0.98)1.59 ± 0.402.82 ± 0.791.39 ± 0.270.88 ± 0.181.67 ± 0.60
 TT454.90 ± 0.941.53 (1.52)1.43 ± 0.302.74 ± 0.811.33 ± 0.210.89 ± 0.181.55 ± 0.39
F0.002−1.3504.2440.8600.7180.1060.608
P0.9620.1770.0400.3550.3980.7450.436

Maonan/female
 CC/CT3145.09 ± 1.011.21 (0.82)1.67 ± 0.402.96 ± 0.811.41 ± 0.210.89 ± 0.191.66 ± 0.46
 TT684.88 ± 0.991.21 (0.61)1.59 ± 0.362.83 ± 0.811.35 ± 0.220.84 ± 0.191.67 ± 0.43
F1.799−0.8001.6391.3023.3413.3650.135
0.1810.4240.2010.2550.0680.0670.714

Han/male
 CC/CT2334.95 ± 0.861.16 (0.78)1.78 ± 0.442.85 ± 0.631.37 ± 0.260.92 ± 0.211.58 ± 0.48
 TT355.31 ± 1.061.09 (0.61)1.84 ± 0.433.22 ± 0.871.41 ± 0.270.98 ± 0.221.52 ± 0.53
F5.189−0.9740.8359.5171.2502.7970.179
0.0240.3300.3620.0020.2640.0960.672

Han/female
 CC/CT3184.84 ± 0.931.07 (0.54)1.86 ± 0.412.80 ± 0.711.38 ± 0.210.83 ± 0.181.72 ± 0.41
 TT604.79 ± 0.980.96 (0.93)1.86 ± 0.402.83 ± 0.771.36 ± 0.210.83 ± 0.181.73 ± 0.46
F0.046−1.1430.3960.1670.0050.1280.262
0.8310.2530.5290.6830.9460.7210.609

TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B; ApoA1/ApoB: the ratio of apolipoprotein A1 to apolipoprotein B. The value of triglyceride was presented as median (interquartile range); the difference among the genotypes was determined by the Wilcoxon–Mann–Whitney test.
3.5. Relevant Factors for Serum Lipid Parameters

Multiple linear regression analyses showed that serum HDL-C and ApoA1 concentrations in the Maonan group were correlated with the PLTP rs4810479 genotypes (; Table 5). Serum HDL-C concentrations in Maonan males, HDL-C and ApoA1 concentrations in Maonan females, and TC and LDL-C concentrations in Han males were associated with the genotypes (; Table 6). In addition to the PLTP rs4810479 genotypes, serum lipid traits in the participants were also influenced by several risk factors such as gender, age, waist circumference, BMI, pulse pressure, diastolic blood pressure, systolic blood pressure, fasting blood glucose, alcohol consumption, and cigarette smoking ( for all; Tables 5 and 6).


LipidRisk factorBStd. errorBetat

Maonan and Han

TCWaist circumference0.0180.0030.1625.487<0.001
Age0.0070.0020.1063.688<0.001
Height−0.0100.003−0.088−2.9870.003
Diastolic blood pressure0.0050.0020.0662.2930.022

TGWaist circumference0.0380.0030.30211.155<0.001
Alcohol consumption0.2980.0730.1094.106<0.001
Glucose0.0690.0220.0823.1420.002
Diastolic blood pressure0.0080.0030.0813.0240.003

HDL-CWaist circumference−0.0120.002−0.245−6.804<0.001
Ethnic group0.1890.0220.2258.779<0.001
Alcohol consumption0.1350.0330.1284.045.<0.001
Gender0.1230.0310.1433.996<0.001
Age0.0030.0010.0903.1630.002
Body mass index−0.0100.004−0.082−2.3380.020
Pulse pressure−0.0020.001−0.060−2.1230.034
Cigarette smoking0.0670.0330.0671.9870,047

LDL-CWaist circumference0.0170.0030.1996.917<0.001
Age0.0070.0010.1254.499<0.001
Height−0.0090.003−0.096−3.2910.001

ApoA1Waist circumference−0.0030.001−0.103−2.4530.014
Alcohol consumption0.1520.0190.2647.792<0.001
Gender0.0760.0180.1624.191<0.001
Cigarette smoking0.0640.0190.1173.3110.001
Weight−0.0030.001−0.127−2.8310.005

ApoBWaist circumference0.0060.0010.28010.346<0.001
Age0.0020.0000.1364.914<0.001
Diastolic blood pressure0.0010.0000.0732.6240.009
Glucose0.0100.0040.0652.3990.017

ApoA1/ApoBWaist circumference−0.0140.002−0.244−6.668<0.001
Alcohol consumption0.2140.0380.1805.552<0.001
Gender0.1610.0350.1664.532<0.001
Age−0.0030.001−0.082−3.0650.002
Body mass index−0.0150.005−0.107−2.9980.003
Cigarette smoking0.0890.0390.0792.2940.022
Glucose−0.0220.010−0.060−2.2340.026

Maonan
TCWaist circumference0.0250.0040.2335.810<0.001
Age0.0110.0030.1654.291<0.001
Gender0.2850.0790.1443.601<0.001

TGWaist circumference0.0380.0040.3459.209<0.001
Glucose0.0840.0290.1062.9040.004
Diastolic blood pressure0.0070.0030.0892.3670.018
Alcohol consumption0.2010.0900.0832.2270.026

HDL-CWaist circumference−0.0140.002−0.333−8.635<0.001
Genotype−0.1120.038−0.110−2.9710.003
Alcohol consumption0.1500.0440.1573.4440.001
Gender0.0940.0380.1172.5030.013

LDL-CWaist circumference0.0230.0040.2626.566<0.001
Gender02630.0660.1604.018<0.001
Age0.0090.0020.1523.981<0.001

ApoA1Waist circumference−0.0060.001−0.219−5.605<0.001
Alcohol consumption0.1400.0270.2455.132<0.001
Gender0.1010.0260.2113.909<0.001
Cigarette smoking0.0820.0290.1432.8290.005
Genotype−0.0540.023−0.089−2.3610.019

ApoBWaist circumference0.0080.0010.38510.056<0.001
Age0.0020.0000.1814.945<0.001
Gender0.0420.0150.1092.8660.040

ApoA1/ApoBWaist circumference−0.0220.002−0.390−10.608<0.001
Alcohol consumption0.2240.0450.1844.499<0.001
Age−0.0040.001−0.110−3.0230.003

Han
TCDiastolic blood pressure0.0110.0030.1283.1530.002
Age0.0060.0030.0982.4780.013
Body mass index0.0240.0120.0852.1260.034

TGWaist circumference0.0390.0060.2666.837<0.001
Alcohol consumption0.3700.1140.1233.2490.001
Diastolic blood pressure0.0080.0040.0771.9950.046

HDL-CWaist circumference−0.0110.003−0.215−3.871<0.001
Body mass index−0.0160.007−0.120−2.1590.031

LDL-CAge0.0070.0020.1554.003<0.001
Body mass index0.0310.0080.1403.608<0.001

ApoA1Alcohol consumption0.1680.0230.2887.189<0.001
Weight−0.0070.001−0.282−7.052<0.001

ApoBWaist circumference0.0050.0010.1894.863<0.001
Gender−0.1000.018−0.248−5.554<0.001
Diastolic blood pressure0.0030.0010.1423.766<0.001
Glucose0.0180.0050.1213.2860.001
Height−0.0030.001−0.121−2.6750.008

ApoA1/ApoBBody mass index−0.0390.005−0.275−7.287<0.001
Glucose−0.0420.013−0.124−3.360<0.001
Gender0.2130.0400.2325.3590.001
Alcohol consumption0.2310.0510.2004.540<0.001
Diastolic blood pressure−0.0040.002−0.105−2.8240.005

TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B; ApoA1/ApoB: the ratio of apolipoprotein A1 to apolipoprotein B; B: unstandardized coefficient; Beta: standardized coefficient.

LipidRisk factorBStd. errorBetat

Maonan/male

TCWeight0.0290.0050.3325.320<0.001
Glucose0.1030.0410.1512.5270.012
Pulse pressure−0.0100.003−0.190−2.8310.005
Age0.0100.0040.1612.2760.024

TGWaist circumference0.0540.0080.4016.975<0.001
Glucose0.1790.0540.1913.3210.001
Alcohol consumption0.3650.1420.1482.5740.011

HDL-CWaist circumference−0.0150.002−0.353−6.195<0.001
Alcohol consumption0.1700.0440.2213.883<0.001
Genotype−0.1340.057−0.133−2.3480.020

LDL-CWeight0.0240.0050.3104.954<0.001
Alcohol consumption−0.2030.095−0.128−2.1230.035
Pulse pressure−0.0100.003−0.212−3.1430.002
Age0.0090.0040.1642.2970.022

ApoA1Alcohol consumption0.1530.0310.2934.898<0.001
Waist circumference−0.0050.002−0.186−3.2310.001
Cigarette smoking0.0850.0310.1622.7130.007

ApoBWaist circumference0.0050.0020.2342.3420.020
Glucose0.0250.0080.1833.2540.001
Pulse pressure−0.0020.001−0.200−3.1640.002
Age0.0020.0010.1792.6380.009
Weight0.0040.0020,2422.3190.021

ApoA1/ApoBWaist circumference−0.0210.004−0.343−6.021<0.001
Alcohol consumption0.3010.0640.2674.691<0.001
Systolic blood pressure0.0030.0010.1312.3130.022

Maonan/female
TCAge0.0190.0040.2715.469<0.001
Waist circumference0.0240.0060.1973.997<0.001
Glucose−0.0850.042−0.102−2.0350.043

TGWaist circumference0.0330.0040.3577.518<0.001
Age0.0080.0030.1433.0090.003

HDL-CWaist circumference−0.0140.002−0.288−5.861<0.001
Genotype−0.1000.050−0.098−1.9920.047

LDL-CAge0.0130.0030.2354.870<0.001
Waist circumference0.0200.0050.2094.264<0.001
Alcohol consumption0.6190.2970.1022.0860.038

AopA1Waist circumference−0.0060.001−0.221−4.423<0.001
Genotype−0.0670.028−0.120−2.4060.017

ApoBWaist circumference0.0080.0010.3517.481<0.001
Age0.0040.0010.2765.847<0.001
Glucose−0.0160.008−0.097−2.0270.043

ApoA1/ApoBWaist circumference−0.0200.003−0.377−7.697<0.001
Systolic blood pressure−0.0030.001−0.168−3.545<0.001
Height0.0100.0040.1392.9070.004

Han/male
TCDiastolic blood pressure0.0140.0050.1873.1210.005
Genotype0.3600.1590.1362.2690.024

TGWaist circumference0.0510.0100.2904.939<0.001
Alcohol consumption0.3800.1650.1352.3020.022

HDL-CWeight−0.0160.003−0.299−4.959<0.001
Alcohol consumption0.1330.0530.1512.5040.013

LDL-CGenotype0.3720.1190.1863.1360.002
Body mass index0.0290.0120.1492.5070.013
Glucose0.0600.0270.1322.2300.027

ApoA1Alcohol consumption0.1930.0300.3686.383<0.001
Weight−0.0080.002−0.276−4.784<0.001

ApoBBody mass index0.0120.0040.1973.3220.001
Glucose0.0280.0080.1993.4260.001
Diastolic blood pressure0.0030.0010.1592.6810.008

ApoA1/ApoBWeight−0.0190.003−0.337−5.821<0.001
Alcohol consumption0.2340.0580.2394.050<0.001
Glucose−0.0510.019−0.156−2.7170.007

Han/female
TCAge0.0140.0040.2083.986<0.001
Height−0.0200.008−0.130−2.5050.013

TGWaist circumference0.0290.0060.2344.573<0.001
Diastolic blood pressure0.0140.0050.1452.8250.005

HDL-CWaist circumference−0.0090.004−0.184−2.2590.024
Body mass index−0.0230.011−0.169−2.0770.039

LDL-CAge0.0140.0030.2655.363<0.001
Body mass index0.0270.0120.1122.2750.023

ApoA1Body mass index−0.0150.003−0.220−4.364<0.001
ApoBAge0.0040.0010.2865.829<0.001
Body mass index0.0120.0030.2054.241<0.001
Cigarette smoking−0.1560.058−0.130−2.6630.008

ApoA1/ApoBAge−0.0060.001−0.209−4.279<0.001
Cigarette smoking0.4130.133−0.1513.0960.002
Body mass index−0.0400.007−0.287−5.970<0.001

TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA1: apolipoprotein A1; ApoB: apolipoprotein B; ApoA1/ApoB: the ratio of apolipoprotein A1 to apolipoprotein B; B: unstandardized coefficient; Beta: standardized coefficient. The correlation among serum lipid parameters and the genotypes and several environmental factors was determined by multivariable linear regression analyses with stepwise modeling.

4. Discussion

The current study revealed that the Maonan ethnic group had higher TG and lower HDL-C concentrations than the Han ethnic group ( for each). There were no significant differences in the TC, LDL-C, ApoA1, and ApoB concentrations and the ApoA1/ApoB ratio between the Maonan and Han populations ( for all). It is common knowledge that dyslipidemia is one of the major changeable cardiovascular risk factors and is a major predictor of CVD mortality [1]. The difference in serum lipid profiles between the two populations may be due to distinct environmental, genetic factors and their interactions. Maonan nationality is one of 55 minorities in China. Being a mountain ethnic group, Maonan has its own unique history, custom, and culture, such as intraethnic marriages, specific clothing, inimitable lifestyle, and dietary habits. Most Maonan people are engaged in agricultural production, supplemented by animal husbandry, aquaculture, and other sideline industries. Rice and corn are their staple food, and pumpkin, sweet potato, and millet are the complementary foods. The preference for acidic food is the greatest feature of their diet culture. They have unique eating habits and lifestyles compared to other ethnic groups. Maonan ethnic group advocates intraethnic marriages. Their marriages are mostly arranged by parents. These results suggest that the genetic traits of some genes related to lipid metabolism may be different between the Maonan and Han ethnic groups.

According to the results of the International 1000 Genomes database (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/), we knew that the rs4810479C allele frequency was 26.37% in British in England and Scotland (GBR); 27.27% in Utah residents (CEPH) with Northern and Western European Ancestry (CEU); 32.45% in Colombians from Medellin, Colombia (CLM); 33.84% in Finnish in Finland (FIN); 41.67% in African Caribbean individuals in Barbados (ACB); 42.62% in Americans of African Ancestry in the southwestern USA (ASW); 43.43% in Esan in Nigeria (ESN); 51.46% in Gujarati Indian from Houston, Texas (GIH); 55.34% in Han Chinese in Beijing, China (CHB); 57.56% in Bengali from Bangladesh (BEB); 64.29% in Southern Han Chinese (CHS); and 68.82% in Chinese Dai in Xishuangbanna, China (CDX). In the present study, we found that the Maonan ethnic group had lower rs4810479C allele frequency than the Han ethnic group (55.61% vs. 60.45%, ). The genotype distribution of the PLTP rs4810479 SNP in the present study was also different between the two ethnic groups , but there was no significant difference in the genotype and allele frequencies between males and females in both populations. These findings suggest that the PLTP rs4810479 SNP may have a racial/ethnic specificity.

The association between the PLTP rs4810479 SNP and serum lipid concentrations in different racial/ethnic groups is still largely unclear. In a previous GWAS, Musunuru et al. [36] prompted that the PLTP rs4810479 SNP was associated with HDL-C concentrations in European populations. In the present study, we noted that the PLTP rs4810479 SNP was significantly associated with several serum lipid phenotypes in the Maonan and Han populations. Subgroup analyses of serum lipid profiles according to sex showed that the C allele carriers had higher HDL-C concentrations in Maonan males and lower TC and LDL-C concentrations in Han males than the C allele noncarriers. These results indicate that there might be a race- and/or sex-specific association between the PLTP rs4810479 SNP and serum lipid traits in our study ethnic groups.

It is well known that serum lipid concentrations are also affected by many environmental risk factors such as population features, life style, diet structure, and physical inactivity [37]. In the current study, we also found that serum lipid concentrations were associated with several environmental risk factors in both ethnic groups. In a previous research study, we found that the intakes of total dietary fat, cholesterol, and energy were higher in Maonan than in Han ethnic groups [30]. The difference in living environment, eating habits, life style, and genetic background between the two populations may be the main cause of different serum lipid concentrations. Rice, corn, and other carbohydrate-rich foods are the daily staple foods of the Maonan people. They are also good at making various complementary foods with rice. They like to eat spicy and acidic foods that contain a lot of oil and salt. The intake of a large amount of carbohydrate, oil, and salt can increase the waist circumference and blood pressure in the Maonan people. Several studies have shown that long-term high-salt diet is an important risk factor to affect blood pressure levels [38, 39]. A meta-analysis showed that reduced sodium intake can lower blood pressure levels in people with or without hypertension [40]. In addition, the people of Maonan also like to eat pork, beef, and/or animal offals in a hot pot which is rich in saturated fatty acids. Many previous studies have shown that diet alone can explain the variation in blood lipid levels [41]. Long-term high-saturated fat diets are strongly associated with obesity, hypertension, dyslipidemia, and atherosclerosis [42, 43]. Therefore, different environmental risk factors such as unhealthy lifestyle and diet structure may further alter the association between genetic variation and blood lipid concentrations in our research populations.

Our work may have some limitations. First, we could not exclude the influence of diet and other environmental risk factors in the statistical analyses. Second, we also could not rule out the effect of asymptomatic diseases. Third, an association between the PLTP rs4810479 SNP and serum lipid concentrations was observed in this study, but many unmeasured factors should be considered including genetic and environmental risk factors. Finally, the sample size in our study populations is a bit small. Therefore, it is necessary to further expand the sample size, especially the gene-gene, gene-environment, and environment-environment interactions on serum lipid parameters to confirm our findings.

5. Conclusions

There was a significant difference in the genotype and allele distribution of the PLTP rs4810479 SNP between the Maonan and Han populations. The association between the PLTP rs4810479 SNP and serum lipid parameters was also different between the two nationalities and between males and females. There may be a racial/ethnic- and/or sex-specific association between the PLTP rs4810479 SNP and serum lipid concentrations in our study populations.

Abbreviations

ANCOVA:Analysis of covariance
Apo:Apolipoprotein
BMI:Body mass index
BPI:Bactericidal/permeability-increasing protein
CAAD:Carotid artery disease
CAD:Coronary artery disease
CETP:Cholesterol ester transfer protein
CVD:Cardiovascular disease
DNA:Deoxyribonucleic acid
GWAS:Genome-wide association study
HDL-C:High-density lipoprotein cholesterol
LBP:Lipopolysaccharide-binding protein
LDL-C:Low-density lipoprotein cholesterol
LPS:Lipopolysaccharide
PCR:Polymerase chain reaction
PLTP:Phospholipid transfer protein
PLTPa:PLTP activity
RFLP:Restriction fragment length polymorphism
SNP:Single-nucleotide polymorphism
TC:Total cholesterol
TG:Triglyceride
UTR:Untranslated region.

Data Availability

The datasets generated during the present study are not publicly available because detailed genetic information of each participant was included in these materials.

Disclosure

There was no role of the funding body in the design of the study and collection, analysis, and interpretation of the data and in writing the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

F.-H. Z. conceived the study, participated in the design, undertook genotyping, performed the statistical analyses, and drafted the manuscript. R.-X. Y. conceived the study, participated in the design, carried out the epidemiological survey, collected the samples, and helped to draft the manuscript. L.-M. Y., W.-X. L., J.-Z. W., and D.-Z. Y. carried out the epidemiological survey and collected the samples. All authors read and approved the final manuscript.

Acknowledgments

The authors are grateful for the funding support provided by the National Natural Science Foundation of China (no. 81460169). They also greatly thank all the participants of this study.

References

  1. G. A. Roth, C. Johnson, A. Abajobir et al., “Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015,” Journal of the American College of Cardiology, vol. 70, no. 1, pp. 1–25, 2017. View at: Google Scholar
  2. M. J. Chapman, H. N. Ginsberg, P. Amarenco et al., “Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management,” European Heart Journal, vol. 32, no. 11, pp. 1345–1361, 2011. View at: Publisher Site | Google Scholar
  3. B. Lamarche, J.-P. Després, S. Moorjani, B. Cantin, G. R. Dagenais, and P.-J. Lupien, “Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study,” Atherosclerosis, vol. 119, no. 2, pp. 235–245, 1996. View at: Publisher Site | Google Scholar
  4. A. V. Khera, M. Cuchel, M. de la Llera-Moya et al., “Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis,” New England Journal of Medicine, vol. 364, no. 2, pp. 127–135, 2011. View at: Publisher Site | Google Scholar
  5. I. M. Graham, A. L. Catapano, and N. D. Wong, “Current guidelines on prevention with a focus on dyslipidemias,” Cardiovascular Diagnosis and Therapy, vol. 7, no. Suppl 1, pp. S4–S10, 2017. View at: Publisher Site | Google Scholar
  6. Y. Ruixing, C. Yuming, P. Shangling et al., “Effects of demographic, dietary and other lifestyle factors on the prevalence of hyperlipidemia in Guangxi Hei Yi Zhuang and Han populations,” European Journal of Cardiovascular Prevention & Rehabilitation, vol. 13, no. 6, pp. 977–984, 2006. View at: Publisher Site | Google Scholar
  7. S. Kathiresan, O. Melander, D. Anevski et al., “Polymorphisms associated with cholesterol and risk of cardiovascular events,” New England Journal of Medicine, vol. 358, no. 12, pp. 1240–1249, 2008. View at: Publisher Site | Google Scholar
  8. D. M. Waterworth, S. L. Ricketts, K. Song et al., “Genetic variants influencing circulating lipid levels and risk of coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 11, pp. 2264–2276, 2010. View at: Publisher Site | Google Scholar
  9. N. J. Samani, J. Erdmann, A. S. Hall et al., “Genomewide association analysis of coronary artery disease,” New England Journal of Medicine, vol. 357, no. 5, pp. 443–453, 2007. View at: Publisher Site | Google Scholar
  10. C. J. Willer, S. Sanna, A. U. Jackson et al., “Newly identified loci that influence lipid concentrations and risk of coronary artery disease,” Nature Genetics, vol. 40, no. 2, pp. 161–169, 2008. View at: Publisher Site | Google Scholar
  11. T. M. Teslovich, K. Musunuru, A. V. Smith et al., “Biological, clinical and population relevance of 95 loci for blood lipids,” Nature, vol. 466, no. 7307, pp. 707–713, 2010. View at: Publisher Site | Google Scholar
  12. C. J. Willer, E. M. Schmidt, S. Sengupta et al., “Discovery and refinement of loci associated with lipid levels,” Nature Genetics, vol. 45, no. 11, pp. 1274–1283, 2013. View at: Publisher Site | Google Scholar
  13. A. Yazdanyar, C. Yeang, and X. C. Jiang, “Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport,” Current Atherosclerosis Reports, vol. 13, no. 3, pp. 244–248, 2011. View at: Publisher Site | Google Scholar
  14. X.-C. Jiang, W. Jin, and M. M. Hussain, “The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism,” Nutrition & Metabolism, vol. 9, no. 1, p. 75, 2012. View at: Publisher Site | Google Scholar
  15. X.-C. Jiang, “Impact of phospholipid transfer protein in lipid metabolism and cardiovascular diseases,” Advances in Experimental Medicine and Biology, vol. 1276, no. 1, pp. 1–13, 2020. View at: Publisher Site | Google Scholar
  16. T. Oka, T. Kujiraoka, M. Ito et al., “Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive,” Journal of Lipid Research, vol. 41, no. 10, pp. 1651–1657, 2000. View at: Publisher Site | Google Scholar
  17. J. R. Day, J. J. Albers, C. E. Lofton-Day et al., “Complete cDNA encoding human phospholipid transfer protein from human endothelial cells,” Journal of Biological Chemistry, vol. 269, no. 12, pp. 9388–9391, 1994. View at: Publisher Site | Google Scholar
  18. D. T. Valenta, N. Ogier, G. Bradshaw et al., “Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1572–1578, 2006. View at: Publisher Site | Google Scholar
  19. C. M. Desrumaux, P. A. Mak, W. A. Boisvert et al., “Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells,” Journal of Lipid Research, vol. 44, no. 8, pp. 1453–1461, 2003. View at: Publisher Site | Google Scholar
  20. K. D. O’Brien, S. Vuletic, T. O. McDonald et al., “Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis,” Circulation, vol. 108, no. 3, pp. 270–274, 2003. View at: Google Scholar
  21. T. Tzotzas, C. Desrumaux, and L. Lagrost, “Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor,” Obesity Reviews, vol. 10, no. 4, pp. 403–411, 2009. View at: Publisher Site | Google Scholar
  22. R. P. F. Dullaart, M. Vergeer, R. de Vries, P. J. W. H. Kappelle, and G. M. Dallinga-Thie, “Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity,” Journal of Internal Medicine, vol. 271, no. 5, pp. 490–498, 2012. View at: Publisher Site | Google Scholar
  23. J. Huuskonen, V. M. Olkkonen, M. Jauhiainen, and C. Ehnholm, “The impact of phospholipid transfer protein (PLTP) on HDL metabolism,” Atherosclerosis, vol. 155, no. 2, pp. 269–281, 2001. View at: Publisher Site | Google Scholar
  24. Y. Si, Y. Zhang, X. Chen et al., “Phospholipid transfer protein deficiency in mice impairs macrophage reverse cholesterol transport in vivo,” Experimental Biology and Medicine, vol. 241, no. 13, pp. 1466–1472, 2016. View at: Publisher Site | Google Scholar
  25. G. Song, C. Zong, M. Shao et al., “Phospholipid transfer protein (PLTP) deficiency attenuates high fat diet induced obesity and insulin resistance,” Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1864, no. 10, pp. 1305–1313, 2019. View at: Publisher Site | Google Scholar
  26. D. S. Kim, A. A. Burt, J. E. Ranchalis et al., “PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity,” Journal of Lipid Research, vol. 56, no. 7, pp. 1351–1362, 2015. View at: Publisher Site | Google Scholar
  27. G. P. Jarvik, R. Rajagopalan, E. A. Rosenthal et al., “Genetic and nongenetic sources of variation in phospholipid transfer protein activity,” Journal of Lipid Research, vol. 51, no. 5, pp. 983–990, 2010. View at: Publisher Site | Google Scholar
  28. S. Kathiresan, C. J. Willer, G. M. Peloso et al., “Common variants at 30 loci contribute to polygenic dyslipidemia,” Nature Genetics, vol. 41, no. 1, pp. 56–65, 2009. View at: Publisher Site | Google Scholar
  29. M. Vergeer, S. M. Boekholdt, M. S. Sandhu et al., “Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility,” Circulation, vol. 122, no. 5, pp. 470–477, 2010. View at: Publisher Site | Google Scholar
  30. Y. Wang, L. H. Aung, J. Y. Tan et al., “Prevalence of dyslipidemia and its risk factors in the Chinese Maonan and Han populations,” International Journal of Clinical and Experimental Pathology, vol. 9, no. 10, pp. 10603–10616, 2016. View at: Google Scholar
  31. L. Qiu, R.-X. Yin, E. Khounphinith, F.-H. Zhang, D.-Z. Yang, and S.-L. Pan, “Association of the APOA1 rs964184 SNP and serum lipid traits in the Chinese Maonan and Han populations,” Lipids in Health and Disease, vol. 17, no. 1, p. 105, 2018. View at: Publisher Site | Google Scholar
  32. People’s Republic of China--United States Cardiovascular and Cardiopulmonary Epidemiology Research Group, “An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People’s Republic of China. Baseline report from the P.R.C.-U.S.A. Collaborative study. People’s Republic of China--United States cardiovascular and cardiopulmonary epidemiology research group,” Circulation, vol. 85, no. 3, pp. 1083–1096, 1992. View at: Publisher Site | Google Scholar
  33. L. Miao, R.-X. Yin, S.-L. Pan, S. Yang, D.-Z. Yang, and W.-X. Lin, “Association between the MVK and MMAB polymorphisms and serum lipid levels,” Oncotarget, vol. 8, no. 41, pp. 70378–70393, 2017. View at: Publisher Site | Google Scholar
  34. Q.-H. Zhang, R.-X. Yin, H. Gao et al., “Association of the SPTLC3 rs364585 polymorphism and serum lipid profiles in two Chinese ethnic groups,” Lipids in Health and Disease, vol. 16, no. 1, p. 1, 2017. View at: Publisher Site | Google Scholar
  35. L. Miao, R.-X. Yin, S.-L. Pan, S. Yang, D.-Z. Yang, and W.-X. Lin, “BCL3-PVRL2-TOMM40 SNPs, gene-gene and gene-environment interactions on dyslipidemia,” Scientific Reports, vol. 8, no. 1, p. 6189, 2018. View at: Publisher Site | Google Scholar
  36. K. Musunuru, S. P. Romaine, G. Lettre et al., “Multi-ethnic analysis of lipid-associated loci: the NHLBI CARe project,” PLoS One, vol. 7, no. 5, Article ID e36473, 2012. View at: Publisher Site | Google Scholar
  37. Y. Ruixing, F. Qiming, Y. Dezhai et al., “Comparison of demography, diet, lifestyle, and serum lipid levels between the Guangxi Bai Ku Yao and Han populations,” Journal of Lipid Research, vol. 48, no. 12, pp. 2673–2681, 2007. View at: Publisher Site | Google Scholar
  38. K. J. Aaron and P. W. Sanders, “Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence,” Mayo Clinic Proceedings, vol. 88, no. 9, pp. 987–995, 2013. View at: Publisher Site | Google Scholar
  39. P. Rust and C. Ekmekcioglu, “Impact of salt intake on the pathogenesis and treatment of hypertension,” Advances in Experimental Medicine and Biology, vol. 956, no. 1, pp. 61–84, 2017. View at: Publisher Site | Google Scholar
  40. N. J. Aburto, A. Ziolkovska, L. Hooper, P. Elliott, F. P. Cappuccio, and J. J. Meerpohl, “Effect of lower sodium intake on health: systematic review and meta-analyses,” BMJ, vol. 346, no. apr03 3, p. f1326, 2013. View at: Publisher Site | Google Scholar
  41. Y. Joffe, M. Collins, and J. Goedecke, “The relationship between dietary fatty acids and inflammatory genes on the obese phenotype and serum lipids,” Nutrients, vol. 5, no. 5, pp. 1672–1705, 2013. View at: Publisher Site | Google Scholar
  42. S. Chiu, P. T. Williams, and R. M. Krauss, “Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial,” PLoS One, vol. 12, no. 1, Article ID e0170664, 2017. View at: Publisher Site | Google Scholar
  43. A. D. von Frankenberg, A. Marina, X. Song, H. S. Callahan, M. Kratz, and K. M. Utzschneider, “A high-fat, high-saturated fat diet decreases insulin sensitivity without changing intra-abdominal fat in weight-stable overweight and obese adults,” European Journal of Nutrition, vol. 56, no. 1, pp. 431–443, 2017. View at: Publisher Site | Google Scholar

Copyright © 2021 Fen-Han Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views199
Downloads287
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.